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INTRODUCTION 
Achieving earlier diagnosis of cancer has 
been a part of the strategy for improving 
cancer outcomes in England since 2000, 
when an urgent GP referral pathway for 
suspected cancer, requiring that patients 
should wait no more than 2 weeks to be 
seen (here termed a 2-Week Wait (2WW) 
referral) was introduced.1 The Cancer 
Reform Strategy2 identified early diagnosis 
as being critical to improved survival, a 
priority recently reiterated in Improving 
Outcomes: a Strategy for Cancer.3 It led to 
the National Awareness and Early Diagnosis 
Initiative,4 a series of actions intended to 
understand and address the reasons for 
later diagnosis of cancer in England. 
Implicit in the 2WW referral pathway in 
England is the intention that the majority of 
cancers should be diagnosed by this route, 
while efficient use of the pathway would be 
demonstrated by the precision of its use. As 
increasingly detailed data on 2WW referrals 
has become available at a national level, 
it is apparent that a significant proportion 
of cancers reach a diagnosis by other 
routes (in 2007 only 25% of cancers were 
diagnosed through the 2WW pathway),5 
while the proportion of 2WW referrals found 
to have cancer has fallen from 13% in 2006–
2007 to 11% in 2009–2010.6 The criteria for 
2WW referral have long been considered to 
be too narrowly defined7 and there is wide 
variation in compliance with the guidelines 
for its use.8 Nevertheless, efficient referral 
practice, underpinned by NICE advice,9 is 
now a key part of the Quality, Innovation, 
Productivity and Prevention (QIPP) agenda 
for the NHS.10 Furthermore, fast-track 
referral for suspected cancer is being viewed 
as a valuable diagnostic option elsewhere in 
Europe as countries seek to improve their 
cancer survival statistics.11,12
More recently, the amount of variation in 
use of the 2WW pathway between practices 
and primary care trusts has been a cause 
for concern for the National Audit Office6 
and the Public Accounts Committee,13 
both of which have recommended that this 
should be investigated and addressed by 
commissioners. Every practice in England 
can now access its cancer profile, a set of 24 
measures relating to cancer screening and 
diagnosis, produced by the National Cancer 
Intelligence Network in December 2010, 
which includes data on 2WW referrals and is 
intended to support quality improvement in 
this area.14 The interpretation of these profiles, 
however, has been hampered by uncertainty 
among GPs and Cancer Networks as to what 
represents best practice. 
This study examined use by practices 
of the 2WW referral pathway and related 
this to all cancer diagnoses on the Cancer 
Waiting Times Database (CWT-Db) to 
identify patterns of use that might represent 
good practice.
Method
Data, including patient’s NHS number, 
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Abstract
Background 
A 2-Week Wait (2WW) referral pathway for 
earlier diagnosis of suspected cancer was 
introduced in England in 2000. Nevertheless, 
a significant proportion of patients with cancer 
are diagnosed by other routes (detection rate), 
only a small proportion of 2WW referrals 
have cancer (conversion rate) and there is 
considerable between-practice variation. 
Aim
This study examined use by practices of 
the 2WW referral in relation to all cancer 
diagnoses.
Design and setting
A cross-sectional analysis of data extracted 
from the Cancer Waiting Times Database for 
all 2WW referrals in 2009 and for all patients 
receiving a first definitive treatment in the same 
year.
Method
The age standardised referral ratio, conversion 
rate, and detection rate were calculated for 
all practices in England and the correlation 
coefficient for each pair of measures. The 
median detection rate was calculated for each 
decile of practices ranked by conversion rate 
and vice versa, performing nonparametric tests 
for trend in each case. 
Results
Data for 8049 practices, 865 494 referrals, and 
224 984 cancers were analysed. There were 
significant correlations between referral ratio 
and conversion rate (inverse) and detection 
rate (direct). There was also a direct correlation 
between conversion and detection rates. There 
was a significant trend in conversion rate for 
deciles of detection rate, and vice versa, with 
a marked difference between the lowest and 
higher deciles.
Conclusion
There is a consistent relationship between 
2WW referral conversion rate and detection 
rate that can be interpreted as representing 
quality of clinical practice. The 2WW referral 
rate should not be a measure of quality of 
clinical care. 
Keywords
cancer diagnosis; quality of care; primary care; 
referral.
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were extracted from the national CWT-Db 
for all 2WW referrals with a date first seen 
in 2009 and for all patients receiving a first 
definitive treatment for cancer (including, 
as well as conventional treatments, active 
monitoring and declined treatment) with a 
treatment start date in 2009.
The patient’s registered GP practice (as 
at mid-2010) and demographic information 
(including date of birth and postcode) were 
obtained by tracing patients (using the 
NHS Open Exeter Batch Tracing Service) 
according to their NHS number. 
The age-standardised referral ratio, 
conversion rate, and detection rate were 
calculated for all practices in England, 
excluding those with a list size <1000 
and those where different data sources 
indicated a considerable change in list size, 
suggesting practice mergers or closures. 
The measures were calculated in 
accordance with the methodology used for 
producing practice cancer profiles15 and are 
defined as follows:
• Referral ratio — the indirectly 
standardised number of 2WW referrals 
relative to the GP list size. 
• Conversion rate — the proportion of 
2WW referrals which result in a cancer 
diagnosis (positive predictive value [PPV]).
• Detection rate — the proportion 
of cancers treated which were 2WW 
referrals (sensitivity).
How this fits in
There is considerable variation in GPs’ 
use of the 2-week referral pathway for 
suspected cancer, in the proportion of 
those referrals that prove to have cancer 
(conversion rate) and in the proportion 
of all cancer diagnosed by this pathway 
(detection rate). This study shows a 
relationship between the latter two 
measures that represents quality of clinical 
practice and has potential as a quality 
indicator.
British Journal of General Practice, September 2012  e591
Table 1. Referral, conversion, and detection rates, by various factors
 Number of Age-sex   
Factor GP practices standardised RR 95% CI CR 95% CI DR 95% CI
Total 8049 100.00  0.11 (0.11 to 0.11) 0.43 (0.43 to 0.43)
Age, years    
<65 8049   0.07 (0.07 to 0.07) 0.42 (0.41 to 0.42) 
≥65 8048   0.17 (0.17 to 0.17) 0.44 (0.46 to 0.44)
Practice deprivation 
Least deprived 1385 97.78 (97.33 to 98.23) 0.11 (0.11 to 0.12) 0.44 (0.43 to 0.44) 
2 1423 101.12 (100.67 to 101.58) 0.12 (0.11 to 0.12) 0.44 (0.43 to 0.44) 
3 1513 103.59 (103.12 to 104.06) 0.11 (0.11 to 0.12) 0.44 (0.44 to 0.44) 
4 1654 102.68 (102.20 to 103.17) 0.11 (0.11 to 0.11) 0.43 (0.42 to 0.43) 
Most deprived 2074 96.03 (95.53 to 96.54) 0.10 (0.10 to 0.10) 0.40 (0.39 to 0.40)
SHA 
North East 380 113.60 (112.60 to 114.60) 0.11 (0.11 to 0.12) 0.42 (0.41 to 0.42) 
North West 1243 101.81 (101.23 to 102.39) 0.11 (0.11 to 0.11) 0.42 (0.42 to 0.43) 
Yorkshire & the Humber 789 95.59 (94.94 to 96.25) 0.13 (0.12 to 0.13) 0.43 (0.42 to 0.43) 
East Midlands 613 103.39 (102.66 to 104.12) 0.12 (0.12 to 0.12) 0.45 (0.44 to 0.45) 
West Midlands 934 105.42 (104.75 to 106.09) 0.10 (0.10 to 0.11) 0.43 (0.42 to 0.44) 
East of England 776 98.31 (97.69 to 98.93) 0.11 (0.11 to 0.12) 0.42 (0.42 to 0.43) 
London 1478 89.35 (88.80 to 89.90) 0.09 (0.09 to 0.09) 0.38 (0.37 to 0.39) 
South East Coast 623 106.16 (105.43 to 106.89) 0.10 (0.10 to 0.11) 0.45 (0.44 to 0.46) 
South Central 497 93.64 (92.91 to 94.37) 0.12 (0.12 to 0.12) 0.47 (0.46 to 0.47) 
South West 716 105.20 (104.55 to 105.86) 0.12 (0.12 to 0.13) 0.45 (0.46 to 0.46)
Referral ratioa 
High 1949 147.06 (146.59 to 147.54) 0.09 (0.09 to 0.09) 0.48 (0.47 to 0.48) 
Average 3106 99.39 (99.04 to 99.73) 0.12 (0.12 to 0.12) 0.44 (0.44 to 0.44) 
Low 2994 61.09 (60.81 to 61.37) 0.14 (0.14 to 0.15) 0.37 (0.37 to 0.37)
Practice list size 
>6000 3920 104.12 (103.87 to 104.37) 0.11 (0.11 to 0.11) 0.44 (0.44 to 0.44) 
3001–6000 2555 94.35 (93.89 to 94.80) 0.11 (0.11 to 0.11) 0.41 (0.41 to 0.42) 
≤3000 1574 76.17 (75.44 to 76.90) 0.12 (0.12 to 0.12) 0.37 (0.36 to 0.38)
aHigh and low groups include practices with a standardised referral ratio which is significantly higher or lower than 100. The average group includes all other practices.  
CR = conversion rate. DR = detection rate. RR = referral ratio. SHA = strategic health authority.
Scatter plots were constructed and 
correlation coefficients were calculated 
for each of the three pairs of the three 
measures. As the rates are not normally 
distributed and the relationships are non-
linear, Spearman’s rank correlation was 
used, which is based on the relative orders 
of the rates. The relationships between 
variables was also investigated for different 
patient and practice subgroups, based on 
patient’s age (<65 and ≥65 years), practice 
socioeconomic deprivation (IMD quintiles),16 
practice list size, strategic health authority 
(SHA) and 2WW referral rates. The median 
detection rate was calculated also for each 
decile of practices ranked by conversion 
rate and the median conversion rate for 
each decile of practices ranked by detection 
rate. A nonparametric test for trend17 in 
detection rate was performed by deciles of 
conversion rate and vice versa. The analyses 
were performed using Stata (version 12).
RESULTS
Data on 865 494 2WW referrals and 224 984 
cancers from 8049 of the 8229 practices 
in the 2008–2009 Quality and Outcomes 
Framework database were analysed.18 
Table 1 shows the calculated referral, 
conversion and detection rates, overall and 
by patient and practice subgroups.
Of all 2WW referrals, 11% (n = 96 561) 
resulted in a cancer diagnosis (conversion 
rate). Diagnoses resulting from 2WW 
referrals accounted for 43% of all first 
treatments for cancer recorded on the CWT 
database (detection rate). 
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Figure 1. Correlation between age-sex standardised referral ratio and conversion rate.
Figure 2. Correlation between age-sex 
standardised referral ratio and detection rate.
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After adjusting for age and sex, there 
was significant variation in standardised 
referral ratios, particularly by practice list 
size and SHA, but there was no significant 
deprivation gradient. Significantly lower 
conversion rates were found in the most 
deprived areas, for those aged <65 years 
and those practices with higher referral 
ratios. Lower detection rates were found 
in the most deprived areas, for those aged 
<65 years, those practices with low referral 
ratios and those practices with smaller list 
sizes. 
Correlations between the three measures
An inverse relationship between 
standardised referral ratio and conversion 
rate was found; that is, those with higher 
2WW referral ratios generally have lower 
conversion rates (correlation coefficient 
–0.35, P<0.001) (Figure 1).
A direct relationship between 
standardised referral ratio and detection 
rate was found; that is, those practices with 
higher referral ratios generally have higher 
detection rates (correlation coefficient 0.42, 
P<0.001) (Figure 2). 
Finally, a direct relationship between 
conversion and detection rates was found 
also; that is, those practices with higher 
conversion rates generally have higher 
detection rates and vice versa (correlation 
coefficient 0.37, P<0.001) (Figure 3).
The correlations, between the 
standardised 2WW referral ratio and 
conversion rate, standardised 2WW referral 
ratio and detection rate, and conversion 
and detection rates remained significant 
when calculated for all patient and practice 
subgroups. (Table 2).
There was a statistically significant 
(P<0.001) trend in detection rate, for deciles 
of practices based on conversion rate; the 
median detection rate increased from 
17% for practices in the lowest decile of 
conversion rate to 45–46% for practices in 
the highest four deciles of conversion rate. 
There was also a statistically significant 
(P<0.001) trend in conversion rate, for 
deciles of detection rate; the median 
conversion rate increasing from 4% to 14%, 
for practices in the lowest to highest deciles 
of detection rate. In both cases, there was 
a marked difference between the lowest 
decile and all higher deciles. (Figure 3)
DISCUSSION
Summary
There was a significant correlation between 
2WW referral conversion and detection 
rates such that practices with higher 
conversion rates also tended to have higher 
detection rates and vice versa. 
Everything else being equal, practices 
with low 2WW referral ratios would 
expect a high proportion of their referrals 
to be diagnosed with the disease (high 
conversion rate) compared with high-
referring practices. Practices with low 2WW 
referral ratios would also expect a higher 
proportion of their patients to be diagnosed 
with cancer via other routes, such as 
following routine referrals or emergency 
presentation (low detection rate). These 
expected relationships have been borne 
out in the results of this study. They also 
imply that practices with high conversion 
rates would expect to have low detection 
rates, and vice versa. However, this study’s 
results indicate that the opposite is true. 
Because the positive correlation observed 
between conversion rate and detection rate 
is significant across a wide range of patient 
and practice subgroups, it represents an 
intrinsic difference in diagnostic quality 
between practices; that is, a quality gradient.
As conversion rate increases, there is 
a ceiling effect in the increasing detection 
rate trend. Reasons for this include 
screen-detected cancers, patients not 
presenting to the GP with 2WW-qualifying 
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Figure 3. Correlation between conversion rate and detection rate (with lines plotting the median detection rate 
within deciles of conversion rate and the median conversion rate within deciles of detection rate).
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alarm symptoms and diagnoses made as 
emergencies without prior presentation 
to the GP. However, as detection rate 
increases there is a continuing trend for 
increasing conversion rate, despite being 
skewed by the poor PPV of many cancer 
alarm symptoms, reflecting the accuracy 
with which the 2WW criteria are applied.
Strengths and limitations
On average a practice will have 27 new 
cancer diagnoses each year recorded in 
the CWT-Db. As a result, individual practice 
conversion rates and detection rates lack 
precision. However, this study’s finding 
of a relationship between detection and 
conversion rates is based on an analysis 
of data for almost all of the practices in 
England, more than 8000 in total, and for 
865 000 referrals and 225 000 cancers. The 
observed correlation between these two 
measures is therefore very unlikely to have 
occurred by chance and is not subject to bias 
in the selection of practices. Furthermore, 
the relationship is evident across all of the 
patient and practice subgroups investigated. 
Collection of the data used in this analysis 
is mandatory for all NHS provider trusts 
in England, meaning that these findings 
are nationally representative. It is also 
done according to agreed definitions and 
systematic data collection bias is therefore 
unlikely. However, as 2009 was the first 
year that cancer waiting times data were 
recorded according to a new system19 it 
is possible that the number of referrals 
may have been under-recorded in some 
hospitals, with some resulting inaccuracies 
in referral, conversion and detection rates 
for some practices.
Some patients diagnosed with cancer 
are not recorded in the CWT-Db; for 
example, those who die prior to treatment 
commencing or who receive treatment 
privately,20 or who are diagnosed outside 
the hospital setting. In 2009, the number of 
cases recorded on the CWT-Db was 15% 
less than the number of cases (excluding 
non melanoma skin cancer) registered by 
cancer registries,21 although there are some 
Table 2. Correlations between referral, conversion and detection rates, by various factors
Factor RR versus CR 95% CI RR versus DR 95% CI  CR versus DR 95% CI
Total –0.35 (–0.37 to –0.33) 0.42 (0.40 to 0.44) 0.37 (0.35 to 0.39)
Age, year    
  <65 –0.21 (–0.23 to –0.19) 0.29 (0.27 to 0.31) 0.57 (0.55 to 0.58) 
  ≥65 –0.28 (–0.30 to –0.26) 0.41 (0.40 to 0.43) 0.44 (0.42 to 0.45)
Practice deprivation 
  Least deprived –0.43 (–0.47 to –0.38) 0.38 (0.34 to 0.43) 0.35 (0.30 to 0.40) 
  2 –0.45 (–0.49 to –0.41) 0.41 (0.36 to 0.45) 0.28 (0.23 to 0.33) 
  3 –0.39 (–0.44 to –0.35) 0.39 (0.35 to 0.43) 0.34 (0.29 to 0.38) 
  4 –0.39 (–0.43 to –0.35) 0.42 (0.38 to 0.46) 0.35 (0.30 to 0.39) 
  Most deprived –0.23 (–0.27 to –0.19) 0.44 (0.41 to 0.48) 0.46 (0.43 to 0.50)
SHA 
  North East –0.56 (–0.63 to –0.49) 0.37 (0.28 to 0.45) 0.29 (0.19 to 0.38) 
  North West –0.42 (–0.46 to –0.37) 0.44 (0.40 to 0.49) 0.30 (0.25 to 0.35) 
  Yorkshire & the Humber –0.43 (–0.49 to –0.37) 0.43 (0.37 to 0.48) 0.32 (0.25 to 0.38) 
  East Midlands –0.41 (–0.48 to –0.34) 0.44 (0.37 to 0.50) 0.29 (0.21 to 0.36) 
  West Midlands –0.24 (–0.30 to –0.18) 0.46 (0.41 to 0.51) 0.45 (0.40 to 0.50) 
  East of England –0.39 (–0.45 to –0.33) 0.42 (0.36 to 0.48) 0.37 (0.31 to 0.43) 
  London –0.30 (–0.35 to –0.25) 0.41 (0.36 to 0.45) 0.46 (0.42 to 0.50) 
  South East Coast –0.43 (–0.49 to –0.36) 0.33 (0.25 to 0.40) 0.33 (0.26 to 0.40) 
  South Central –0.38 (–0.45 to –0.30) 0.39 (0.31 to 0.46) 0.34 (0.26 to 0.42) 
  South West –0.49 (–0.54 to –0.43) 0.40 (0.33 to 0.46) 0.28 (0.21 to 0.34)
RRa 
  High –0.32 (–0.36 to –0.28) 0.14 (0.09 to 0.18) 0.53 (0.50 to 0.56) 
  Average –0.15 (–0.18 to –0.11) 0.11 (0.08 to 0.15) 0.61 (0.59 to 0.63) 
  Low –0.11 (–0.15 to –0.08) 0.41 (0.38 to 0.44) 0.54 (0.52 to 0.57)
Practice list size 
  >6000 –0.45 (–0.48 to –0.43) 0.36 (0.33 to 0.39) 0.31 (0.28 to 0.34) 
  3001–6000 –0.34 (–0.37 to –0.30) 0.42 (0.39 to 0.45) 0.40 (0.37 to 0.43) 
  ≤3000 –0.22 (–0.27 to –0.18) 0.43 (0.39 to 0.47) 0.51 (0.48 to 0.55)
aHigh and low groups include practices with a standardised referral ratio which is significantly higher or lower than 100. The average group includes all other practices.  
CR = conversion rate. DR = detection rate. RR = referral ratio. SHA = strategic health authority.
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differences in the definitions used for these 
two data sources. In the current analysis, 
cases not recorded on the CWT-Db will 
not contribute to a practice’s conversion 
or detection rate. However, is not expected 
to have a significant impact on the study’s 
conclusions.
The number of cancers and number of 
referrals used to calculate the practice 
measures are based on slightly different 
cohorts of patients. Specifically, the number 
of 2WW referrals is taken as the number 
of cases first seen in the hospital receiving 
the referral in 2009, whereas the number 
of cancers is taken as the number of 
cases starting treatment in 2009. Although 
most patients first seen in 2009 will also 
have started treatment in that year, some 
patients starting treatment in 2009 will have 
been first seen in 2008 and some patients 
first seen in 2009 will not have started 
treatment until some time in 2010. This 
may have a small effect on the conversion 
and detection rates for some practices but 
the effect does not result in a systematic 
bias in any single direction.
Differential availability and use of 
direct access to diagnostic tests between 
practices and hospitals may have an 
effect on 2WW referral rates and resulting 
conversion and detection rates, particularly 
where use results in patients bypassing 
the 2WW pathway. For example, in some 
integrated respiratory medicine services, 
a patient suspected of having lung cancer 
following a GP referral for chest X-ray 
may be seen and diagnosed by a specialist 
without going through the 2WW pathway 
and will not contribute to that practice’s 
2WW detection rate. Similarly, patients 
diagnosed following referral from a 
national screening programme will also not 
contribute to their practice’s detection rate.
Some cancers are more likely to be 
diagnosed as emergencies than others.5 
The case mix of cancers in any one practice 
will therefore affect its referral, conversion 
and detection rates. However, in this 
study the correlations between measures 
remained consistent across all subgroups, 
and notably within all deprivation groups 
and geographical areas.
Comparison with existing literature
Referral rates from general practice have 
been extensively studied and a recent 
Scottish study has reported a sixfold 
variation between practices in referral 
rates for their equivalent of 2WW referral.22 
A National Cancer Intelligence Network 
analysis of referral ratios for England has 
shown that 15% of practices made less 
than half the average number of 2WW 
referrals, while 10% made over 50% more 
than the average number of referrals.23 
The 11% conversion rate reflects the low 
predictive value of cancer symptoms, even 
those regarded as alarm symptoms,24 
while the 43% detection rate reflects the 
finding of a Danish study that around 50% 
of patients with cancer do not present with 
alarm symptoms.25 The factors influencing 
referral, however, remain incompletely 
understood. A study using the General 
Practice Research Database found that 
morbidity explained 30% of total variation, 
whilst that attributable to practices was only 
5%.26 Socioeconomic status of the practice 
population explains about a quarter of the 
observed variation.27,28 A significant part of 
the variation remains unexplained and may 
relate to intrinsic psychological variables 
on the part of the GP and hospital supply 
factors.29 This study has highlighted that 
referral rates alone are a poor measure of 
quality of clinical care. 
The current findings of a negative 
correlation between referral ratios and 
conversion rates and positive correlation 
between referral ratios and detection 
rates are consistent with earlier studies; 
for example of breast and gynaecological 
cancer 2WW referrals, where a downward 
trend in conversion rates was observed as 
referrals rose in the years after introduction 
of the urgent referral pathway.30,31
Implications for research and practice
A high conversion rate implies efficient 
use of the 2WW referral pathway. A high 
detection rate implies that fewer patients 
are being diagnosed by routes that are 
either slower, such as routine referrals, or 
as emergencies, a route associated with 
poorer outcomes.32 A high conversion rate 
together with a high detection rate (top right 
quadrant, Figure 3) therefore constitutes 
an indicator of good clinical practice and 
the positive correlation found across all 
practices represents a quality gradient in 
cancer referral practice. Furthermore, 
practices in the top left quadrant (low 
conversion, high detection) may be overusing 
the 2WW referral pathway, while those in 
the bottom right quadrant (high conversion, 
low detection) may not be using it enough. 
Those practices in the bottom left quadrant 
(low conversion, low detection) may be poor 
at case selection, implying poor clinical 
practice. These interpretations can help 
practices to interpret their practice cancer 
profiles, can inform a more meaningful 
dialogue between primary care, secondary 
care and cancer networks and allows them 
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to measure improvement over time. 
The Quality and Outcomes Framework 
(QOF) contains only two indicators for 
cancer care, neither of which relate to 
earlier diagnosis. These findings show that 
two separate, readily available measures 
of diagnostic performance (conversion rate 
and detection rate) are correlated in such 
a way as to offer a means of distinguishing 
good and poor referral practice, and could 
serve as the basis for a QOF indicator. 
Further modelling is required, however, 
to investigate the feasibility of developing 
a robust indicator based on these two 
measures which takes into account both 
systematic and random variation between 
practices.
These findings can inform QIPP 
initiatives, notably those intended to reduce 
inappropriate referrals. For cancer, 2WW 
referral rate alone is not a measure of 
quality, and the relationship between 
conversion and detection rates is more 
important. Similar relationships may be 
evident in other clinical areas. For example, 
practice quality of care (overall clinical 
QOF score) has already been shown to 
be associated with risk of admission for 
angina.33 The analysis of referrals to rapid 
access chest pain clinics using this study’s 
approach may allow new insights into 
quality of cardiovascular care. 
Practice cancer profiles were provided 
to practices for the first time in 2010 and, 
by repeating this analysis in 2011, their 
impact on conversion and detection should 
be apparent. Further detailed study of those 
practices that achieve high conversion and 
high detection rates may give insights into 
the direction for future quality improvement 
initiatives for cancer diagnosis in general 
practice. Conversely, the use of cancer-
specific audit and significant event analysis 
may help practices with low conversion and 
detection rates to identify where they may 
have scope for improvement.34
There remains a need for more detailed 
analyses of these data, to investigate 
possible explanations for why those 
practices with the lowest conversion rates 
also tend to have much lower detection 
rates (and vice-versa) and to determine 
whether the quality gradient is consistent 
across individual cancer sites and how 
it impacts on patient outcomes such as 
survival. The routine collection of this data 
also allows the possibility of longitudinal 
research studies of the impact of quality 
improvement initiatives in general practice. 
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